-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DAC-002 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DAC-002 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DAC-002 in Triple-Negative Breast Cancer (TNBC) Drug Details: DAC-002 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DAC-002 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DAC-002 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DAC-002 in Small-Cell Lung Cancer Drug Details: DAC-002 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ecubectedin in Rhabdomyosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ecubectedin in Rhabdomyosarcoma Drug Details: Ecubectedin (PM-14) is under development for the treatment of solid...
-
Product Insights
NewUreter Cancer – Drugs In Development, 2024
Empower your strategies with our Ureter Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra, and enlarged lymph nodes in the groin area. Risk factors include smoking. Treatment includes surgery, chemotherapy, and radiation therapy. The Ureter Cancer drugs in development market research report provide comprehensive information on...
-
Product Insights
NewUrethral Cancer – Drugs In Development, 2024
Empower your strategies with our Urethral Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Urethral cancer is a condition in which cancerous (malignant) cells form tumors in the tissues of urethra. Urethra is the tube through which urine flows out of the bladder. A history of bladder cancer can affect the risk of urethral cancer and it occurs more often in men than in women. The symptoms include blood in urine, discharge or bleeding from the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sym-021 in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sym-021 in Metastatic Biliary Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sym-021 in Metastatic Biliary Tract Cancer Drug Details: Sym-021 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLY-2608 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLY-2608 in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLY-2608 in Metastatic Breast Cancer Drug Details: RLY-2608 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HTL-0039732 in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Sarcomas Drug Details: HTL-0039732 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemvaleukin Alfa in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemvaleukin Alfa in Non-Small Cell Lung Cancer Drug Details: Nemvaleukin alfa (ALKS-4230) is under development...